Successful treatment of cutaneous-onset Erdheim-Chester disease with cobimetinib and anakinra

Clin Exp Dermatol. 2024 Apr 23;49(5):523-525. doi: 10.1093/ced/llae014.

Authors

Italo Francesco Aromolo¹, Chiara Moltrasio^{2

3}, Carlo Alberto Maronese¹, Corrado Campochiaro⁴, Arturo Bonometti⁵, Emilio Berti¹, Emanuela Passoni², Angelo Marzano^{1

2}

Affiliations

¹ Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy.
² Dermatology Unit, IRCCS Foundation Maggiore Policlinico Hospital, Lombardia, Milan, Italy.
³ Department of Medical Surgical and Health Sciences, University of Trieste, Trieste, Friuli-Venezia Giulia, Italy.
⁴ San Raffaele Hospital, Milan, Italy.
⁵ Pathology Unit, Humanitas University, Rozzano, Milan, Italy.

PMID: 38231013
DOI: 10.1093/ced/llae014

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antirheumatic Agents / therapeutic use
Azetidines* / therapeutic use
Drug Therapy, Combination
Erdheim-Chester Disease* / drug therapy
Erdheim-Chester Disease* / pathology
Female
Humans
Interleukin 1 Receptor Antagonist Protein* / therapeutic use
Middle Aged
Piperidines* / therapeutic use
Treatment Outcome

Substances

Antirheumatic Agents
Azetidines
cobimetinib
Interleukin 1 Receptor Antagonist Protein
Piperidines